Adamis pharmaceuticals provides an update on zimhi™

San diego, april 12, 2021 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) today provided an update on the status of the company's new drug application (nda) relating to its zimhi™ high-dose naloxone injection product intended for the treatment of opioid overdose. the company had a type a meeting with the u.s. food and drug administration (fda) to review comments on the additional information provided by the company in response to the fda's previous complete response letter (crl) regarding the nda, and also to obtain input from the agency concerning the resubmission of the nda. adamis believes the meeting was productive and plans to resubmit the nda for zimhi to the fda within the next 45 days, absent unexpected delays. the fda did not provide a detailed timeline for review but did indicate that it would attempt to work in an expeditious manner, acknowledging that the country is in an opioid crisis.
ADMP Ratings Summary
ADMP Quant Ranking